Clinical Trials on Bladder Carcinoma in South Africa

Total 1970 results

Bayer

Completed

FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period (FREEDOM)

Overactive Bladder

South Africa
Lipac Oncology LLC
TesoRx Pharma, LLC

Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Urologic Neoplasms | Urogenital Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Non-Muscle Invasive Bladder Cancer | Urinary Bladder | Bladder Cancer Cell Transitional

United States
Noah Hahn, M.D.
Pfizer; Hoosier Cancer Research Network

Terminated

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Transitional Cell Carcinoma of the Bladder

United States, United Kingdom
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

Bladder Carcinoma | Recurrent Bladder Carcinoma

United States
Telormedix SA

Completed

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Carcinoma in Situ | Non Muscle Invasive Bladder Cancer

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; University of Stellenbosch

Withdrawn

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

HIV Infection | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | FIGO Stage IIB Cervix Carcinoma | FIGO Stage III Cervix Carcinoma | FIGO Stage IVA Cervix Carcinoma

South Africa, Zimbabwe
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States
Matthew Galsky
Novartis Pharmaceuticals; Hoosier Cancer Research Network

Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Urothelial Carcinoma | Bladder Carcinoma

United States
Sesen Bio, Inc.

Completed

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Urinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors

United States, Canada
University of Witwatersrand, South Africa

Unknown

A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women

Cervical Dysplasia

South Africa
Tyra Biosciences, Inc

Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)

Solid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditions

Australia, United States, France, Spain
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Solid Tumor | Bladder Cancer | Non-muscle-invasive Bladder Cancer

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Vaxiion Therapeutics

Completed

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

Urothelial Carcinoma of the Urinary Bladder

United States
University of Witwatersrand, South Africa

Completed

Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women (VICAR2)

Cervical Intraepithelial Neoplasia

South Africa
Medical University of South Carolina

Terminated

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Bladder Cancer

United States
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial Carcinoma

United States
White River Junction Veterans Affairs Medical Center
Medical University of South Carolina; National Cancer Institute (NCI); University...

Recruiting

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance (ReplaceCysto)

Non-muscle-invasive Bladder Cancer

United States
Cell Genesys

Unknown

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Carcinoma, Transitional Cell | Bladder Neoplasms

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

United States, Canada
Fidia Farmaceutici s.p.a.

Recruiting

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Bladder Carcinoma in Situ (CIS)

United States, Spain, Italy, France, Poland
Antiva Biosciences

Completed

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

Cervical Cancer | Human Papilloma Virus | HSIL, High Grade Squamous Intraepithelial Lesions | Cervical Dysplasia | HSIL of Cervix | High-Grade Cervical Intraepithelial Neoplasia | HIV Negative | CIN - Cervical Intraepithelial Neoplasia | Cervical Neoplasm

South Africa
Prokarium Ltd

Recruiting

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)

NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBC

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Astellas Pharma Global Development, Inc.
Seagen Inc.

Recruiting

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBC

United States, Canada, France, Spain, United Kingdom, Germany
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Portugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma

United States
Bristol-Myers Squibb
Pierre Fabre Medicament

Completed

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Kidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, Bladder

United States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
zr Pharma & GmbH
Foundation Medicine

Terminated

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)

Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Muscle Invasive Bladder Cancer | Ureter Carcinoma | Renal Pelvis Carcinoma | Urinary Bladder Carcinoma | Urethra Carcinoma

United States, Spain, France, Italy, Germany, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Hellenic GenitoUrinary Cancer Group

Active, not recruiting

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Bladder Cancer

Greece
Hellenic GenitoUrinary Cancer Group

Recruiting

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

Bladder Cancer

Greece
National and Kapodistrian University of Athens

Completed

Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer

Non-muscle-invasive Bladder Cancer

Greece
Noah Hahn, M.D.
Hoosier Cancer Research Network; Achieve Life Sciences

Completed

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Bladder Cancer | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Antiva Biosciences

Recruiting

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia

Australia, South Africa
Bristol-Myers Squibb

Completed

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Transitional Cell Carcinoma | Bladder Cancer | Metastasis

United States, Korea, Republic of, United Kingdom, Spain, Australia, France, Thailand, Denmark, Poland, Belgium, Italy, Philippines, Canada, Russian Federation, Greece, Indonesia
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
SURGE Therapeutics

Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non-muscle-invasive Bladder Cancer

United States
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Peripheral Electrical Stimulation for the Treatment of Overactive Bladder (PESTOB)

Idiopathic Overactive Bladder

United Kingdom
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Universitätsklinikum Hamburg-Eppendorf
Cancer Research UK; Deutsche Krebshilfe e.V., Bonn (Germany); Australasian Gastro-Intestinal... and other collaborators

Active, not recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

Germany, Netherlands, United Kingdom, Australia, Denmark, Italy, New Zealand, Austria

Clinical Trials on Bladder Carcinoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations